AI Article Synopsis

  • This study compares the efficacy and safety of propofol and remimazolam in elderly patients (60+) undergoing gastrointestinal endoscopic procedures.
  • Propofol is quicker for sedation and shows higher sedation success, while remimazolam has a better safety profile, with lower risks of bradycardia and hypoxemia.
  • The conclusion suggests that while propofol is more effective, remimazolam is safer, and current evidence isn't strong enough to recommend remimazolam as the preferred sedative in this demographic.

Article Abstract

Purpose: Propofol has become the sedative of choice for endoscopy and colonoscopy. However, it has shown associations with various adverse effects, specifically in the geriatric population. In contrast, remimazolam is a novel benzodiazepine, demonstrating a superior clinical safety profile. Hence, this systematic review and meta-analysis aims to clarify the efficacy and safety of remimazolam versus propofol in elderly patients (≥ 60 years) undergoing gastrointestinal endoscopic and colonoscopy procedures.

Methods: Electronic databases including PubMed, Cochrane Library, ScienceDirect, and Google Scholar were explored from inception till January 7, 2024. The Cochrane Risk of Bias Tool for Randomized Controlled Trials (RoB-2) was utilized to evaluate the quality of each included study reported in this meta-analysis.

Results: Seven randomized control trials were included, resulting in the pooling of 1,466 patients (remimazolam: 731 patients; propofol: 735 patients). Propofol demonstrated a significantly lower time to loss of consciousness (P < 0.00001, 4 studies, 784 patients) and a greater sedation success after first dose (P = 0.05, 5 studies, 1,271 patients). Remimazolam reported a significantly lower risk of bradycardia (P = 0.02, 5 studies, 1,323 patients), hypoxemia (P < 0.00001, 6 studies, 1,389 patients), and pain on injection site (P < 0.00001, 5 studies, 1,184 patients). No statistically significant differences in sedation time, number of supplemental doses, procedural parameters, and other adverse outcomes were reported.

Conclusion: As per the results of our analyses, propofol demonstrated comparatively superior efficacy, however, remimazolam demonstrated comparatively superior safety. The debatable evidence generated from this meta-analysis may not currently be powerful enough to advocate for the use of remimazolam in elderly patients undergoing gastrointestinal procedures; hence, further comprehensive studies are necessary in order to arrive at a robust conclusion.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-024-03624-6DOI Listing

Publication Analysis

Top Keywords

remimazolam versus
8
versus propofol
8
endoscopy colonoscopy
8
elderly patients
8
randomized controlled
8
controlled trials
8
patients propofol
8
propofol
5
patients
5
remimazolam
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!